Patent intelligence · US
US 7622444
Methods for using OX-40 ligand to enhance an antigen specific immune response
Methods for using OX-40 ligand to enhance an antigen specific immune response
Patent details — US 7622444
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 24, 2009
- Expiration
- Nov 19, 2029
- Applicant
- Sisters of Providence in Oregon
- Claims
- 11
- CPC classes
- A61K, A61K2039/55516, A61K38/177, A61K39/0005
Quick answer
US 7622444 (Methods for using OX-40 ligand to enhance an antigen specific immune response) is held by Sisters of Providence in Oregon. Status: granted. Granted Nov 24, 2009. Expires Nov 19, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Sisters of Providence in Oregon
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K2039/55516, A61K38/177, A61K39/0005, A61K39/39, A61P
More from Sisters of Providence in Oregon
Related pharmaceutical patents in our USPTO index.
-
US 12364708
Injectable scaffold for treatment of intracranial aneurysms and related technology
granted -
US 12358968
Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer
granted -
US 12336973
Cancer therapeutic compositions and methods targeting DNAse1L3
granted -
US 12329909
Airway management systems for pulmonary disorder treatment
granted -
US 12285397
Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
granted -
US 12185909
System and method for cleansing segments of a luminal network
granted -
US 12150461
Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof
granted -
US 12144801
Methods and compositions for treatment of epileptic disorders
granted
Frequently asked questions
What is US patent 7622444?
US 7622444 (Methods for using OX-40 ligand to enhance an antigen specific immune response) is held by Sisters of Providence in Oregon. Status: granted. Granted Nov 24, 2009. Expires Nov 19, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7622444?
Sisters of Providence in Oregon is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 193 pharmaceutical patents for this assignee.
When does US 7622444 expire?
Our index shows an expiration date of Nov 19, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.